Oxaliplatin: Key analysis of third-generation platinum anti-tumor drugs

First paragraph: content overview
Oxaliplatin, as a third-generation platinum chemotherapy drug, is mainly used for adjuvant treatment of metastatic colorectal cancer and combination therapy for advanced cancer. Its core advantage lies in forming intra-strand cross-links with DNA, inhibiting tumor cell replication, and is effective in some cisplatin-resistant cases. The content will be parsed in turnMechanism of action,clinical indications,Adverse reaction managementandMajor domestic and foreign manufacturers, to help readers systematically understand this important anti-tumor drug.

Paragraph 2: Mechanism of action and clinical value
Oxaliplatin combines with DNA chains by producing hydrated derivatives to form stable Pt-DNA complexes, blocking tumor cell division. Compared with cisplatin, its unique 1,2-diaminocyclohexane carrier group significantly reduces nephrotoxicity, but may induce peripheral neuropathy. In 2004, the FDA approved its combination with 5-FU/leucovorin (FOLFOX regimen), which improved the median survival of patients with metastatic colorectal cancer to 19-20 months and has now become a first-line regimen recommended by NCCN guidelines.

Section 3: Adverse reactions and medication management
Clinical needs to focus ondose-dependent neurotoxicity(85% of patients experience transient paresthesia) andcold sensitivity. It is recommended to adopt a "discontinue-dose" strategy: suspend administration when grade 2 neurotoxicity occurs, and reduce the dose by 25% after symptoms are relieved. Preventive measures include avoiding contact with cold stimuli within 48 hours after administration and using glucose solution for dilution during infusion (sodium chloride is prohibited). The incidence of myelosuppression is lower than that of cisplatin (approximately 5% grade 3-4 neutropenia).

Paragraph 4: Market structure and dosage form characteristics
In the domestic market, oxaliplatin is mainly available as freeze-dried powder for injection (50mg/100mg specifications), which needs to be stored at 2-8°C away from light. The original drug was developed by Sanofi (trade name: Lexadin). Domestic companies that have passed the consistency evaluation include:

Paragraph 5: Treatment status and prospects
As the core component of the FOLFOX/MFOLFOX6 regimen, oxaliplatin increases the 5-year survival rate after stage III colon cancer surgery to 73%. Current research focuses onNanoformulation Development(such as liposome formulations to reduce neurotoxicity) and combination with immune checkpoint inhibitors. It should be noted that its efficacy is related to the UGT1A1 gene polymorphism, and genetic testing is recommended before use. With the development of precision medicine, oxaliplatin will remain important in personalized chemotherapy.

Quote sources:
1. State Drug Administration Drug Instructions (Approval Number: National Drug Approval No. H20000337)
2. "Chinese Colorectal Cancer Diagnosis and Treatment Standards (2023 Edition)"
3. Sanofi’s Roxadine Product Manual
4. NCCN Guidelines Version 1.2024 Colon Cancer